Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.

Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE.

Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9.

2.
3.

Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.

Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE.

J Biol Chem. 2015 Aug 28;290(35):21591-602. doi: 10.1074/jbc.M115.652008. Epub 2015 Jul 10.

4.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS.

Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.

5.

Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.

Kawahara K, Suenobu M, Ohtsuka H, Kuniyasu A, Sugimoto Y, Nakagomi M, Fukasawa H, Shudo K, Nakayama H.

J Alzheimers Dis. 2014;42(2):587-605. doi: 10.3233/JAD-132720.

PMID:
24916544
6.

Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.

Bonet-Costa V, Herranz-Pérez V, Blanco-Gandía M, Mas-Bargues C, Inglés M, Garcia-Tarraga P, Rodriguez-Arias M, Miñarro J, Borras C, Garcia-Verdugo JM, Viña J.

J Alzheimers Dis. 2016;51(3):701-11. doi: 10.3233/JAD-151020.

PMID:
26890773
7.

The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.

Balducci C, Paladini A, Micotti E, Tolomeo D, La Vitola P, Grigoli E, Richardson JC, Forloni G.

J Alzheimers Dis. 2015;46(2):471-82. doi: 10.3233/JAD-150029.

PMID:
25777514
8.

Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis.

Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Heneka MT.

J Neurosci. 2011 May 11;31(19):7049-59. doi: 10.1523/JNEUROSCI.6546-10.2011.

9.

Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA.

Science. 2013 May 24;340(6135):924-g. doi: 10.1126/science.1234114.

10.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Fitz NF, Cronican AA, Lefterov I, Koldamova R.

Science. 2013 May 24;340(6135):924-c. doi: 10.1126/science.1235809.

11.

ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.

Corona AW, Kodoma N, Casali BT, Landreth GE.

J Neuroimmune Pharmacol. 2016 Mar;11(1):61-72. doi: 10.1007/s11481-015-9627-8. Epub 2015 Jul 15.

PMID:
26175148
12.

Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.

Tai LM, Koster KP, Luo J, Lee SH, Wang YT, Collins NC, Ben Aissa M, Thatcher GR, LaDu MJ.

J Biol Chem. 2014 Oct 31;289(44):30538-55. doi: 10.1074/jbc.M114.600833. Epub 2014 Sep 12.

13.

ApoE promotes the proteolytic degradation of Abeta.

Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE.

Neuron. 2008 Jun 12;58(5):681-93. doi: 10.1016/j.neuron.2008.04.010.

14.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B.

Science. 2013 May 24;340(6135):924-e. doi: 10.1126/science.1233937.

15.

RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.

Lefterov I, Schug J, Mounier A, Nam KN, Fitz NF, Koldamova R.

Neurobiol Dis. 2015 Oct;82:132-140. doi: 10.1016/j.nbd.2015.05.019. Epub 2015 Jun 10.

16.

New hope from an old drug: fighting Alzheimer's disease with the cancer drug bexarotene (targretin)?

Aicardi G.

Rejuvenation Res. 2013 Dec;16(6):524-8. doi: 10.1089/rej.2013.1497.

PMID:
24047423
17.

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM.

Science. 2013 May 24;340(6135):924-d. doi: 10.1126/science.1234089.

18.

Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.

Zhao J, Fu Y, Liu CC, Shinohara M, Nielsen HM, Dong Q, Kanekiyo T, Bu G.

J Biol Chem. 2014 Apr 18;289(16):11282-92. doi: 10.1074/jbc.M113.526095. Epub 2014 Mar 5.

19.

Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier.

Bachmeier C, Beaulieu-Abdelahad D, Crawford F, Mullan M, Paris D.

J Mol Neurosci. 2013 Feb;49(2):270-6. doi: 10.1007/s12031-012-9866-6. Epub 2012 Aug 14.

PMID:
22890420
20.

Preclinical success against Alzheimer's disease with an old drug.

LaFerla FM.

N Engl J Med. 2012 Aug 9;367(6):570-2. doi: 10.1056/NEJMcibr1204890. No abstract available.

PMID:
22873540

Supplemental Content

Support Center